

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2015 THIRD QUARTERLY REPORT

本公司（「公司」）之股票在香港聯合交易所有限公司（「香港交易所」）及上海證券交易所（「上海證券交易所」）上市。本公司之股票在香港交易所之股票代號為02196，在上海證券交易所之股票代號為600332。本公司之股票在證券交易所之上市，並不表示本公司之股票符合任何證券交易所之上市要求，亦不表示本公司之股票符合任何證券交易所之上市規則。本公司之股票在證券交易所之上市，並不表示本公司之股票符合任何證券交易所之上市要求，亦不表示本公司之股票符合任何證券交易所之上市規則。

本公司（「公司」）之股票在香港聯合交易所有限公司（「香港交易所」）及上海證券交易所（「上海證券交易所」）上市。本公司之股票在香港交易所之股票代號為02196，在上海證券交易所之股票代號為600332。本公司之股票在證券交易所之上市，並不表示本公司之股票符合任何證券交易所之上市要求，亦不表示本公司之股票符合任何證券交易所之上市規則。本公司之股票在證券交易所之上市，並不表示本公司之股票符合任何證券交易所之上市要求，亦不表示本公司之股票符合任何證券交易所之上市規則。

上海復星醫藥（集團）股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Qiyu
Chairman

2015年9月29日

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu and Mr. Yao Fang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Wang Pinliang, Ms. Kang Lan and Mr. John Changzheng Ma; and the independent non-executive directors of the Company are Dr. Zhang Weijiong, Mr. Cao Huimin, Mr. Jiang Xian and Dr. Wong Tin Yau Kelvin.

* for identification purposes only

2.1 Model of the system

$$C_{\text{MB}} = \frac{C_{\text{MB}}}{C_{\text{MB}}} = 1$$
[illegible]

$$E = \frac{1}{2} \int_{\mathbb{R}^3} |\nabla \phi|^2 dx + \frac{1}{2} \int_{\mathbb{R}^3} |\nabla \psi|^2 dx - \frac{1}{2} \int_{\mathbb{R}^3} \phi^2 dx - \frac{1}{2} \int_{\mathbb{R}^3} \psi^2 dx$$
$$C_{\text{MB}} = \frac{C_{\text{MB}}}{C_{\text{MB}}}$$
[illegible]

2.2 本公司截至2020年12月31日止的年度，本公司的前10名普通股股东持有本公司普通股股份的情况如下：

单位：股

The shareholding status of the Top 10 shareholders				73,142		
Name of shareholders (full name)	Shareholding at the end of the period	Percentage (%)	Number of restricted shares held	Shares pledged or locked up		Capacity
				Status	Number	
HANGHAI FORTUNE HIGH TECHNOLOGY (GROUP) COMPANY LIMITED (“FUTONG”)	920,641,314	39.83	0	None	0	Does not have the right to dispose of the shares
HK CC NOMINEE LIMITED (N/A)	402,619,300	17.42	0	None	0	Does not have the right to dispose of the shares
CHINA ECIFINANCE COMPANY LIMITED	69,112,399	2.99	0	None	0	Does not have the right to dispose of the shares
NATIONAL SOCIAL ECIFINANCE 104 FOLIO*	37,199,998	1.61	0	None	0	Does not have the right to dispose of the shares
HONG KONG ECIFINANCE CLEARING COMPANY LIMITED (N/A)	33,556,005	1.45	0	None	0	Does not have the right to dispose of the shares
CENTRAL HUIJIN INVESTMENT LTD.	24,067,700	1.04	0	None	0	Does not have the right to dispose of the shares
INHA LIFE INVESTMENT CO., LTD. — DIRECTOR — GUY DIRECTOR — 018L — FH001 HANGHAI*	22,652,864	0.98	0	None	0	Does not have the right to dispose of the shares
ING CANAL (BEIJING) CO., LTD. — ING CANAL GROUP HOLDING ND NO. I*	17,695,247	0.77	0	None	0	Does not have the right to dispose of the shares
FORTUNE ING ELECTED I*	16,764,537	0.73	0	None	0	Does not have the right to dispose of the shares
ING AN CO., LTD. — ELIFE INVESTMENT — ING CANAL	16,567,783	0.72	0	None	0	Does not have the right to dispose of the shares

The shareholding status of the Top 10 unrestricted shareholders			
Name of the shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type	Number
EG	920,641,314	MB	920,641,314
HK CC NOMINEE LIMITED (Note 1)	402,619,300	MB	402,619,300
CHINA EC I IE FINANCE CO., LTD. (Note 1)	69,112,399	MB	69,112,399
NA IONAL COIAL EC I F ND 104	37,199,998	MB	37,199,998
HONG KONG EC I IE CLEA ING COM AN	33,556,005	MB	33,556,005
CEN AL H IJIN IN E MEN L D.	24,067,700	MB	24,067,700
INH A LIFE IN ANCE CO., LTD. — DI IDEND — G DI IDEND — 018L — FH001 HANGHAI*	22,652,864	MB	22,652,864
ING CA I AL (BEIJING) CO., LTD. — ING CA I AL G H F ND NO. I*	17,695,247	MB	17,695,247
FIC ING ELEC ED 1*	16,764,537	MB	16,764,537
ING AN CO., LTD. — ELI E IN E MEN • ING CA I AL	16,567,783	MB	16,567,783
D	ING CA I AL (BEIJING) CO., LTD. — ING CA I AL G H F ND NO. I*, FIC ING ELEC ED 1* ING AN CO., LTD. — ELI E IN E MEN • ING CA I AL (BEIJING) CO., LTD. C		
D	N		

Note 1: HK CC NOMINEE LIMITED, H K I K I C, N L

Note 2: HONG KONG EC I IE CLEA ING COM AN LIMITED, MB

2.3

N

3. SIGNIFICANT EVENTS

[illegible]

Balance Sheet				
Items	Closing balance as at the end of the period	Opening balance as at the beginning of the year	Ratio of change	Reasons
● 2020 12 31 止	485,549,599.95	198,755,576.52	144.29%	M 2020 12 31 止
A 2020 12 31 止		990,340,787.62	-100.00%	(N 2020 12 31 止)
● 2020 12 31 止	3,494,730.03	11,246,964.92	-68.93%	M 2020 12 31 止
A 2020 12 31 止	3,529,897,004.62	2,499,156,438.67	41.24%	M 2020 12 31 止
D 2020 12 31 止	167,214,321.23	89,379,481.02	87.08%	M 2020 12 31 止 & D 2020 12 31 止
2020 12 31 止	4,508,065,870.77	2,841,223,392.47	58.67%	M 2020 12 31 止
2020 12 31 止	474,418,367.92	342,926,461.15	38.34%	M 2020 12 31 止
D 2020 12 31 止	14,831,357.70	1,279,819.25	1,058.86%	M 2020 12 31 止
L 2020 12 31 止		589,118,424.34	-100.00%	(N 2020 12 31 止)
N 2020 12 31 止	2,822,255,623.13	1,109,525,523.85	154.37%	M 2020 12 31 止
● 2020 12 31 止	63,116,411.43	1,070,561,681.96	-94.10%	M 2020 12 31 止
L 2020 12 31 止	1,618,247,844.35	771,191,646.56	109.84%	M 2020 12 31 止
B 2020 12 31 止	1,894,480,886.28	3,085,482,735.30	-38.60%	M 2020 12 31 止

Income Statement				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan – Sep 2015	Jan – Sep 2014		
Financial income	339,686,256.62	251,024,209.33	35.32%	Majority of the increase is due to the increase in the income from the sale of financial assets.
Administrative expenses	33,340,027.70	11,784,007.60	182.93%	Majority of the increase is due to the increase in the expenses for the management of the company.
Gain on disposal of subsidiaries	3,506,487.53	-9,516,778.44	136.85%	Majority of the increase is due to the increase in the gain on disposal of subsidiaries.
Net income from operations	63,499,502.52	38,512,060.43	64.88%	Majority of the increase is due to the increase in the income from the sale of financial assets.
Net income from operations	10,862,409.73	15,531,263.99	-30.06%	Majority of the decrease is due to the increase in the expenses for the management of the company.
Net income from operations	-279,141,519.38	146,057,212.28	-291.12%	Majority of the decrease is due to the increase in the expenses for the management of the company.

Statement of Cash Flow				
Items	Current amount	Amount of the last period	Ratio of change	Reasons
	Jan – Sep 2015	Jan – Sep 2014		
Net cash generated from operating activities	1,161,951,526.99	843,637,595.71	37.73%	Mainly due to the increase in the net cash generated from operating activities of the Company in the first nine months of 2015.
Net cash used in investing activities	764,402,303.12	1,793,987,740.16	-57.39%	Mainly due to the decrease in the net cash used in investing activities of the Company in the first nine months of 2015.

[illegible]**Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

指导教师: 陈奇宇

29 2015

4. APPENDICES

4.1 Financial statements

Consolidated balance sheet

30 September 2015

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Currency: MB

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current Assets:		
Cash and cash equivalents	3,516,813,404.78	3,695,698,185.82
Accounts receivable		
Prepaid expenses		
Other current assets	38,724,495.54	33,770,584.14
Financial assets	408,527,911.80	472,523,132.71
Investments	1,789,464,377.02	1,504,149,790.72
Intangible assets	136,605,468.61	137,690,114.05
Goodwill		
Deferred tax assets		
Other non-current assets		
Investments	677,257.70	1,023,889.42
Derivatives	16,983,973.47	14,264,402.96
Other non-current assets	485,549,599.95	198,755,576.52
Investments	1,627,321,198.79	1,604,562,390.25
Assets held for sale		990,340,787.62
Non-current assets		
Long-term investments		
Fixed assets	3,529,897,004.62	2,499,156,438.67
Intangible assets		
Goodwill		
Investments	13,489,435,775.47	11,905,750,117.54
Financial assets		
Derivatives	4,720,292,409.25	4,623,958,317.63
Other non-current assets	964,172,888.14	1,051,988,109.53
Deferred tax assets	3,233,982.94	5,450,698.63
Other non-current assets		
Investments		
Derivatives		
Other non-current assets		
Investments	2,857,317,020.41	2,822,483,093.20
Derivatives	167,214,321.23	89,379,481.02
Goodwill	3,292,538,591.11	3,255,041,739.55
Intangible assets	11,804,369.09	13,583,440.85
Derivatives	92,366,614.48	101,221,671.79
Other non-current assets	262,125,551.28	304,238,328.42
Deferred tax assets	29,390,398,528.02	26,672,251,436.83
Other non-current assets	37,414,560,945.71	35,336,277,255.96

Consolidated balance sheet (Continued)

30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Short-term borrowings	4,508,065,870.77	2,841,223,392.47
Bills payable		
Notes payable		
Accounts payable		
Prepaid expenses		
Other payables	67,928,606.53	70,987,451.05
Payables for employee compensation	874,465,599.33	833,974,948.21
Payables for employee benefits	226,002,022.22	266,518,255.34
Guaranteed payables		
Other current liabilities	296,895,628.48	298,472,746.11
Current liabilities	474,418,367.92	342,926,461.15
Interest payable	166,803,873.32	177,075,081.31
Dividends payable	14,831,357.70	1,279,819.25
Other non-current liabilities	1,379,103,280.44	1,935,656,885.83
Non-current liabilities		
Long-term borrowings		
Long-term payables		
Long-term payables		
Long-term payables		589,118,424.34
Long-term payables	2,822,255,623.13	1,109,525,523.85
Long-term payables	63,116,411.43	1,070,561,681.96
Long-term payables	10,893,886,641.27	9,537,320,670.87
Non-current liabilities:		
Long-term borrowings	1,618,247,844.35	771,191,646.56
Long-term payables	1,894,480,886.28	3,085,482,735.30
Long-term payables	890,883,419.71	710,056,624.65
Long-term payables		
Long-term payables		
Long-term payables	178,123,561.73	139,593,190.51
Long-term payables	1,934,427,964.42	1,929,331,107.42
Long-term payables	73,391,869.13	60,299,392.99
Long-term payables	6,589,555,545.62	6,695,954,697.43
Long-term payables	17,483,442,186.89	16,233,275,368.30
Equity:		
Capital	2,311,380,364.00	2,311,611,364.00
Reserves	6,049,708,237.59	6,123,454,191.14
Reserves		
Reserves		
Reserves	838,468,407.81	1,120,365,125.73
Reserves	1,662,373,054.64	1,662,373,054.64
Reserves		
Reserves	6,700,890,376.05	5,457,045,050.64
Reserves		
Reserves	17,562,820,440.09	16,674,848,786.15
Reserves	2,368,298,318.73	2,428,153,101.51
Reserves	19,931,118,758.82	19,103,001,887.66
Reserves	37,414,560,945.71	35,336,277,255.96

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia



Balance Sheet of the Parent Company (Continued)
30 September 2015

Items	Closing balance as at the end of the Period	Opening balance as at the beginning of the Year
Current liabilities:		
Short-term borrowings	1,834,226,000.00	
Financial liabilities at fair value through profit or loss		
Borrowings		
Borrowings		
Borrowings		
Borrowings		
Borrowings	78,632,661.11	72,568,579.44
Borrowings	23,932,653.33	21,842,286.49
Borrowings	147,159,729.00	160,716,398.26
Borrowings	1,364,923.50	1,062,450.00
Borrowings	453,068,674.16	587,606,051.26
Borrowings	2,641,935,028.99	1,037,216,423.85
Borrowings		998,894,520.55
Borrowings	5,180,319,670.09	2,879,906,709.85
Non-current liabilities:		
Long-term borrowings	186,740,000.00	85,000,000.00
Borrowings	1,894,480,886.28	3,085,482,735.30
Long-term borrowings		
Long-term borrowings		
Long-term borrowings		
Long-term borrowings	1,525,000.00	1,750,000.00
Long-term borrowings	1,209,260,573.79	1,192,857,263.79
Long-term borrowings		
Long-term borrowings	3,292,006,460.07	4,365,089,999.09
Long-term borrowings	8,472,326,130.16	7,244,996,708.94
Equity:		
Paid-up capital (including treasury shares)	2,311,380,364.00	2,311,611,364.00
Capital reserves	8,227,835,906.44	8,270,816,715.22
Long-term equity investments		
Long-term equity investments		
Long-term equity investments	55,747,958.04	224,689,817.57
Long-term equity investments	949,985,460.52	949,985,460.52
Long-term equity investments		
Long-term equity investments	4,193,926,575.18	2,839,595,396.66
Long-term equity investments	15,738,876,264.18	14,596,698,753.97
Long-term equity investments	24,211,202,394.34	21,841,695,462.91

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

January – September 2015

Figure 1: Comparison of the proposed method with the MB method. The proposed method is shown in blue and the MB method is shown in red. The x-axis is the number of iterations and the y-axis is the error. The proposed method shows a faster convergence rate than the MB method.

[illegible]

Consolidated Income Statement (Continued)

January – September 2015

Items	Current Amount (July – September)	Amount of the Last Period (July – September)	Current Amount (January – September)	Amount of the Last Period (January – September)
I. Operating Income	-503,674,636.21	170,383,244.67	-279,141,519.38	146,057,212.28
1. Revenue	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
(i) Revenue from the sale of goods				
1. Revenue from the sale of goods				
2. Revenue from the sale of services				
(ii) Revenue from the sale of goods	-506,044,279.16	169,738,571.45	-281,896,717.92	147,808,244.36
1. Revenue from the sale of goods	732,427.55	-9,352.18	-195,739,333.69	-5,108,705.95
2. Revenue from the sale of services	-440,970,255.91	171,599,596.74	-16,216,735.14	149,088,050.35
3. Revenue from the sale of goods				
4. Revenue from the sale of services				
5. Revenue from the sale of goods	-65,806,450.80	-1,851,673.11	-69,940,649.09	3,828,899.96
6. Revenue from the sale of goods				
Revenue from the sale of goods	2,369,642.95	644,673.22	2,755,198.54	-1,751,032.08
II. Operating Expenses	157,117,103.71	812,100,177.38	1,897,755,696.77	1,940,074,283.26
Cost of goods sold	81,440,708.74	726,766,676.07	1,609,072,739.39	1,722,392,108.74
Operating Expenses	75,676,394.97	85,333,501.31	288,682,957.38	217,682,174.52
III. Operating Profit				
(1) Operating Profit	0.25	0.24	0.82	0.69
(2) Operating Profit	0.25	0.24	0.82	0.69

Legal Representative:
Chen Qiyu

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

[illegible]

$$\frac{1}{2} \left(\frac{1}{2} + \frac{1}{2} \right) = 1$$
[illegible]

Consolidated Statement of Cash Flow (Continued)
January – September 2015

Items	Current Amount (January – September)	Amount of the Last Period (January – September)
III. Cash flow generated from financing activities:		
Cash and cash equivalents	87,721,195.00	1,445,949,451.00
Interest income	87,721,195.00	38,269,850.07
Cash and cash equivalents	5,110,056,682.54	3,475,109,758.30
Cash and cash equivalents	398,929,000.00	1,000,000,000.00
Interest income	40,140,014.05	21,733,509.09
Interest income	5,636,846,891.59	5,942,792,718.39
Cash and cash equivalents	3,519,139,442.58	1,623,242,732.68
Cash and cash equivalents	1,114,614,719.91	1,012,768,967.52
Interest income	268,686,768.21	133,554,721.22
Interest income	238,690,425.98	1,512,793,278.03
Interest income	4,872,444,588.47	4,148,804,978.23
Net increase	764,402,303.12	1,793,987,740.16
IV. Effects of exchange rate fluctuations on cash and cash equivalents	5,949,548.99	14,780,312.38
V. Net increase of cash and cash equivalents		

Statement of Cash Flow of the Parent Company

January – September 2015

上海医药集团股份有限公司 : Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

$$C_{\text{MB}} = \frac{1}{\text{MB}}$$
[illegible]